Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment? Laura Magliulo 1,2 , Marja-Liisa Dahl 2 , Grazia Lombardi 1 , Silvia Fallarini 1 , Laura Maria Villa 3 , Aldo Biolcati 3 , Maria Gabriella Scordo 2 1 DISCAFF Department, ”Amedeo Avogadro” University of Eastern Piedmont, Novara, Italy; 2 Department of Medical Sciences, Clinical Pharmacology, Uppsala University, Sweden; 3 Geriatric Clinical Unit, “Ospedale Maggiore della Caritá” Novara, Italy Corresponding Author: Dr. Maria Gabriella Scordo Department of Medical Sciences, Clinical Pharmacology University of Uppsala Akademiska sjukhuset, Ing. 61 75185 Uppsala - Sweden E-mail: gabriella.scordo@medsci.uu.se Tel: +46 18 6119176 Fax: +46 18 6113703 1 peer-00630268, version 1 - 8 Oct 2011 Author manuscript, published in "European Journal of Clinical Pharmacology 67, 1 (2010) 47-54" DOI : 10.1007/s00228-010-0883-5